CCN(C(C)C)C(C)C.[F:10][C:11]([F:27])([F:26])[C:12]1[CH:17]=[CH:16][C:15]([C:18]2[NH:22][N:21]=[C:20]([C:23]([OH:25])=O)[CH:19]=2)=[CH:14][CH:13]=1.C1C=CC2N(O)N=NC=2C=1.CCN=C=NCCCN(C)C.Cl.Cl.[NH2:51][CH2:52][C:53]([N:55]1[CH2:60][CH2:59][CH:58]([O:61][C:62]2[CH:67]=[CH:66][CH:65]=[CH:64][C:63]=2[Cl:68])[CH2:57][CH2:56]1)=[O:54]>CN(C=O)C.O>[Cl:68][C:63]1[CH:64]=[CH:65][CH:66]=[CH:67][C:62]=1[O:61][CH:58]1[CH2:57][CH2:56][N:55]([C:53](=[O:54])[CH2:52][NH:51][C:23]([C:20]2[CH:19]=[C:18]([C:15]3[CH:14]=[CH:13][C:12]([C:11]([F:10])([F:27])[F:26])=[CH:17][CH:16]=3)[NH:22][N:21]=2)=[O:25])[CH2:60][CH2:59]1DIPEA (150 mg, 1.15 mmol) was added to a stirred solution of 5-(4-trifluoromethyl-phenyl)-1H-pyrazole-3-carboxylic acid (84 mg, 0.33 mmol) (prepared by the method used for the synthesis of Intermediate 29, starting from (p-trifluoromethyl)acetophenone) in DMF (2 mL) followed by HOBt (46 mg, 0.34 mmol) and EDCI.HCl (66 mg, 0.34 mmol). After 2 minutes 2-amino-1-[4-(2-chloro-phenoxy)-piperidin-1-yl]-ethanone hydrochloride (prepared according to Step 1 and 5 of the General Scheme) (100 mg, 0.33 mmol) was added to the reaction mixture and stirring was continued at ambient temperature overnight. The reaction mixture was diluted with cold water, extracted with ethyl acetate and dried over sodium sulfate. The organic layer was concentrated under reduced pressure to afford the residue. The residue was purified by washing with mixture of ethyl acetate and methanol to afford 80 mg (48.2% Yield) of 5-(4-trifluoromethyl-phenyl)-1H-pyrazole-3-carboxylic acid {2-[4-(2-chloro-phenoxy)-piperidin-1-yl]-2-oxo-ethyl}-amide. LC/MS [M+H]+: 507, 92.02%. 1H NMR (300 MHz, DMSO-d6): δ13.7 (d, 1H), 8.0 (m, 3H), 7.8 (m, 2H), 7.44 (d, 1H), 7.24 (m, 3H), 6.96 (m, 1H), 4.7 (m, 1H), 4.2 (d, 2H), 3.7 (m, 2H), 3.4 (m, 2H), 1.9 (m, 2H), 1.6 (m, 2H).